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Available online 16 August 2016The neurodegenerative disease spinocerebellar ataxia type 3 (SCA3) is caused by a CAG-repeat expansion in the
ATXN3 gene. In this study, induced pluripotent stem cell (iPSC) lines were established from two SCA3 patients.
Dermal ﬁbroblasts were reprogrammed using an integration-freemethod and the resulting SCA3 iPSCs were dif-
ferentiated into neurons. These neuronal lines harbored the disease causing mutation, expressed comparable
levels of several neuronal markers and responded to the neurotransmitters, glutamate/glycine, GABA and acetyl-
choline. Additionally, all neuronal cultures formed networks displaying synchronized spontaneous calcium oscil-
lationswithin 28 days ofmaturation, and expressed themature neuronalmarkers NeuN and Synapsin 1 implying
a relatively advanced state of maturity, although not comparable to that of the adult human brain. Interestingly,
we were not able to recapitulate the glutamate-induced ataxin-3 aggregation shown in a previously published
iPSC-derived SCA3 model. In conclusion, we have generated a panel of SCA3 patient iPSCs and a robust protocol
to derive neurons of relatively advanced maturity, which could potentially be valuable for the study of SCA3 dis-
ease mechanisms.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Spinocerebellar ataxia type 3 (SCA3) is a rare autosomal dominantly
inherited neurodegenerative disease caused by a CAG-repeat expansion
mutation in the ATXN3 gene, coding for a polyglutamine (polyQ) stretch
in the protein ataxin-3. In healthy individuals, the CAG-repeat length
spans from 10 to 51, whereas the repeat length in SCA3 patients ranges
from 45 to 87, thus 45 to 51 repeats can result in either healthy or dis-
ease phenotypes (Matos et al., 2011). Although expanded (exp)-
ataxin-3 is expressed throughout the human body (Paulson et al.,
1997), only certain brain areas are affected in SCA3.Magnetic resonance
imaging and macroscopic investigations of SCA3 brains have revealed
severe atrophy of the hindbrain (cerebellum and brain stem) (Rüb et
al., 2006; Scherzed et al., 2012). Histological studies have conﬁrmed
neuronal loss in these areas and several other brain areas (reviewed
by Rüb et al., 2008). This degeneration results in a variety of symptomsClinical and Animal Sciences,
, Denmark.
.
sholm, Denmark.
. This is an open access article underofwhich themost common is progressive ataxia (Matos et al., 2011). Ul-
timately, SCA3 patients encounter approximately 15 years reduction in
life expectancy (Kieling et al., 2007).
Although the CAG-expansion in ATXN3 is known to cause SCA3, the
underlying cellular mechanisms leading to neurodegeneration are not
fully elucidated. It has been proposed that the polyQ expansion alters nor-
mal ataxin-3 functions in for example endoplasmic reticulum associated
degradation (ERAD) and transcriptional regulation (Matos et al., 2011).
The polyQ repeat expansion also leads to the formation of SDS-insoluble
exp.-ataxin-3 aggregated oligomers and large neuronal intranuclear in-
clusions (NIIs) (Ellisdon et al., 2006), of which especially the oligomers
are thought to be toxic (Pellistri et al., 2013). Aggregates can sequester
proteins from diverse cellular processes (Chai et al., 2002; Matos et al.,
2011; Mori et al., 2012) and may also disturb the cellular quality control
systems, such as the ubiquitin proteasome system and autophagy by
overloading (Matos et al., 2011). A prevailing hypothesis is that cleavage
of exp.-ataxin-3 is important for its aggregation, as C-terminal polyQ con-
taining fragments of exp.-ataxin-3 seed ataxin-3 aggregation and induce
cell death to a higher extend than full length exp.-ataxin-3 (Goti, 2004).
Additionally, fragments of ataxin-3 have been detected in affected brain
areas of SCA3 patients but not in unaffected areas or in brains of healthythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
307S.K. Hansen et al. / Stem Cell Research 17 (2016) 306–317controls (Goti, 2004). In particular the role of calpain-mediated ataxin-3
cleavage in SCA3 pathogenesis is supported by convincing evidence
(Hübener et al., 2013; Koch et al., 2011).
Functional studies investigating molecular mechanisms of neurode-
generative diseases are generally limited by the lack of reliable in vitro
models of human neurons. Induced pluripotent stem cell (iPSC)-derived
neurons are a potential solution to this problem and several disease
models have already been generated and published (Reviewed by Corti
et al., 2015). Theﬁrst iPSC lines derived fromSCA3 patientswere reported
by Koch et al. (Koch et al., 2011). In that study, SDS-insoluble exp.-ataxin-
3 aggregates could be induced by stimulationwith glutamate. This aggre-
gation could be prevented by calpain inhibition, supporting the hypothe-
sis that glutamate induced calcium inﬂux activates calpains, which
subsequently mediates the cleavage and aggregation of exp-ataxin-3. In
the present study, we aimed at creating iPSCs from SCA3 patient ﬁbro-
blasts by a non-integratingmethod, as integration of reprogramming vec-
tors might lead to insertional mutagenesis and has been shown to
decrease the differentiation capacity of iPSCs (Sommer et al., 2010). We
strived to obtain a model system with increased resemblance to the af-
fected regions of SCA3 brains by applying a differentiation method,
which favored the development of hindbrain neurons. Furthermore, we
sought to obtainmature neurons to approximate the situation in SCA3pa-
tients where pathology develops in late childhood at earliest (Kieling et
al., 2007). Finally, we investigatedwhether glutamate-induced SDS-insol-
uble exp-ataxin-3 aggregates similar to those detected by Koch et al.
could be observed in our neurons.
2. Materials and methods
2.1. Reprogramming of ﬁbroblasts to iPSCs
The studywas approvedby theEthics Committee of the Capital Region
of Denmark (H-4-2011-157), andwritten informed consentwas obtained
from all patients before enrollment. iPSC lines were created from two
SCA3 patients (patient characteristics are summarized in Table S1).
SCA3patient dermalﬁbroblastswere obtained from forearm skin biopsies
and reprogrammed as previously described (Hansen et al., 2016a, 2016b).
Brieﬂy, ﬁbroblasts were electroporated with the episomal plasmids
pCXLE-hUL (L-MYC, LIN28, Adgene #27080), pCXLE-hSK (SOX2, KLF4,
Adgene #27078) and pCXLE-hOCT4-shp53-F (OCT4, shP53, Adgene
#27077) (Okita et al., 2011). iPSCs were cultured in mTeSR1 (Stem Cell
Technologies, 05850) with 0.1 % penicillin-streptomycin (ThermoFisher
Scientiﬁc, 15140-122) on hESC-qualiﬁed matrigel (BD Biosciences,
354277). Three well-characterized control iPSC lines [K1_shP53 (K1),
K2_shP53 (K2) andK3_shP53 (K3), deposited in the European Bank of in-
duced Pluripotent Stem Cells (EBiSC) as BIONi010-A, BIONi010-B and
BIONi010-C, respectively] derived fromnormal human dermalﬁbroblasts
(Lonza, CC-2511) applying the same reprogramming protocol
(Rasmussen et al., 2014) were also investigated in this study.
2.2. Neuronal differentiation
Differentiation of iPSCs to neural stem cells (NSCs) was performed
using pluripotent stem cell (PSC) neural induction medium
(ThermoFisher Scientiﬁc, A1647801). iPSCs were treated with neural in-
duction medium (NIM) containing 98% neurobasal medium
(ThermoFisher Scientiﬁc, 21103-049), 2% PSC neural induction supple-
ment (ThermoFisher Scientiﬁc, A1647801) and 0.1% penicillin-strepto-
mycin for 7 days. Day 7, non-neural cells were manually removed and
the cells were split with accutase (ThermoFisher Scientiﬁc, A1110501)
and seeded on 100 μg/ml poly-L-ornithine (PLO) (Sigma-Aldrich,
P3655) and 10 μg/ml laminin (LAM) (Sigma-Aldrich, L2020) in neural ex-
pansion medium (NEM) supplemented with 10 μM Rock inhibitor
(Sigma-Aldrich, Y0503). NEM consisted of 49% neurobasal medium
(ThermoFisher Scientiﬁc, 21,103–049), 50% Advanced DMEM⁄F-12
(ThermoFisher Scientiﬁc, 12,634), 1% PSC neural induction supplement(ThermoFisher Scientiﬁc, A1647801) and 0.1% penicillin-streptomycin.
Day 13, the cells were split with accutase and seeded at a density of
1.56 × 105 cells/cm2 for expansion in NEM with Rock inhibitor. Between
day 16–19 NSCs (p2) were frozen in NEM supplemented with 10%
DMSO and 10 μM Rock inhibitor (Sigma-Aldrich, Y0503). NSCs were
thawed (p3), plated at a density of 1.56×105 cells/cm2 expanded and fro-
zen in larger stocks for experiments (p4). Formaturation, NSCs (p6)were
seeded at a density of 1.56 × 105 cells/cm2 in NEM supplemented with
10 μMRock inhibitor on PLO/LAM (day 0). From day 1–28 of maturation,
medium was changed to neuronal maturation medium (NMM)
consisting of 50% DMEM/F12 (ThermoFisher Scientiﬁc, 31,331) and 50%
neurobasal medium, supplemented with 0.5× N2 (ThermoFisher Scien-
tiﬁc, 17,502–048), 0.5× B-27 with vitamin A (ThermoFisher Scientiﬁc,
17504-044), 1.48 mM glutamax-I (ThermoFisher Scientiﬁc, 35,050–
061), 0.5× non-essential amino acids (ThermoFisher Scientiﬁc, 11140-
050), 50 μM 2-mercaptoethanol (ThermoFisher Scientiﬁc, 21985-023),
2.5 μg/ml insulin (Sigma-Aldrich, 19,278), 0.1% penicillin-streptomycin,
20 ng/ml brain-derived neurotrophic factor (BDNF) (RnD Systems, 248-
BD), 10 ng/ml glial cell derived neurotrophic factor (GDNF) (RnD Sys-
tems, 212-GD) and 200 μM ascorbic acid (AA) (Sigma-Aldrich, A5960).
500 μM dibutyryl cyclic adenosine monophosphate (db-cAMP) (Sigma-
Aldrich, D0627) was added to the medium from day 1 to day 21–28. Me-
diumwas changed every 2 days. Day 7 the cells were split with accutase,
seeded at a density of 1.56× 105 cells/cm2 on PLO/LAM inNEMwith Rock
inhibitor and cultured until evaluation in NEM.
2.3. Characterization of iPSCs
The SCA3 iPSC lines were investigated for karyotype, plasmid inte-
gration, expression of pluripotency marker mRNA and protein, in vitro
differentiation and CAG-repeat length as previously described
(Hansen et al., 2016a, 2016b).
2.4. Quantitative real time polymerase chain reaction (qRT-PCR)
For characterization of the neuronal differentiation, cells were har-
vested and reverse transcribed into cDNA with Fast SYBR Green Cells-
to-CT Kit (Ambion, 4402957) according to manufacturer's instructions.
RNA from adult whole brain (6516–1) and fetal whole brain week 22–
30 (636,118) was purchased from Clontech. Fetal hindbrain week 8,5–
9 was kindly provided by Agnete Kirkeby (Lund University). Control
RNA was reverse transcribed with TaqMan reverse transcription re-
agents. qRT-PCR was run with 2× diluted SsoFast EvaGreen Supermix
(Bio\\Rad, 172–5204). CT-values were normalized to the geometric
mean of the housekeeping genes Hsp90AB1, GUSB and RPL13A using
theΔΔCT-method. Primerswere either conventional primers purchased
from Euroﬁns (Table S2) or Taqman primers purchased from Applied
Biosystems (Table S3). The speciﬁcity of the conventional primers was
validated by standard curves, melting curves and gel electrophoresis.
2.5. Fluorescent immunocytochemistry
For characterization of NSCs and neurons, cells were ﬁxed in 4%
paraformaldehyde for 10 min. The cells were blocked in KPBS (0.01 M
phosphate buffer with 150 mM NaCl and 3.4 mM KCl) with 0.5% BSA,
0.1% Triton X-100 and 5% normal swine serum (Jackson
ImmunoResearch, 014–000-121) for 1 h, incubated with primary anti-
bodies (Table S4) in blocking buffer ON at 4 °C and incubated with sec-
ondary antibody and 0.7 μg Hoechst diluted in KPBS for 1 h at RT. The
secondary antibodies were used in 1:800 dilution: Alexa 488 donkey-
anti-mouse (A21202), Alexa 568 donkey-anti-rabbit (A10042), Alexa
488 donkey-anti-goat (A11055), Alexa 594 donkey-anti-rat (A21209)
and Alexa 568 goat-anti-mouse (A11031) purchased from
ThermoFisher Scientiﬁc. The cells were mounted in ﬂuorescent mount-
ingmedium (Dako, S3023) and imageswere captured on aNikon E1000
microscope and processed with ImagePro Plus v7.0.
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ity for the majority of the primary antibodies (Table S4). All secondary
antibodies were tested for unspeciﬁc effects by primary antibody
exclusion.
2.6. Western blot
All western blots were performed with standard methods as previ-
ously described (Hansen et al., 2016a, 2016b).
2.7. Measurement of intracellular calcium kinetics
Neurons grown in 96-well plates were incubated for 1 h with the
ﬂuorescent calcium indicator FLIPR Calcium 5 (Molecular Devices,
R8186) diluted in Hanks balanced salt solution (HBSS) (ThermoFisher
Scientiﬁc, 14175) with 20 mM Hepes (Sigma-Aldrich, H3375) and
1.26 mM CaCl2 (Sigma-Aldrich, C5080). In the experiments investigat-
ing neurotransmitter response Calcium 5 was diluted 2× and the cells
were incubated and recorded at RT. Response to 300 μM glutamate
(Sigma-Aldrich, G100)/10 μM glycine (Sigma-Aldrich, 410,225),
100 μM 5-hydroxy-tryptamine (Sigma-Aldrich, H9523), 25 mM KCl,
100 μM γ-aminobutyric acid (Sigma-Aldrich, A2129), 300 μM acetyl-
choline (Sigma-Aldrich, A6628) and 100 μM dopamine (Sigma-Aldrich,
H60255) was investigated. Three compounds were added in series to
each well, one every 10 min. When investigating spontaneous calcium
oscillations, cells were incubated at 37 °C in 3× diluted Calcium 5 and
HBSS was added after 10 and 20 min, and subsequently 1 μM tetrodo-
toxin (TTX) (Trocis, 1078) after 30 min. Recordings were performed
with an FDSS 7000 Fluorescence Kinetics Plate Reader (Hamamatzu
Photonics) (excitation: 480 nm, emission: 540 nm, sampling frequency:
1 Hz).
2.8. Ataxin-3 aggregation and cleavage
2.8.1. Intracellular calcium
The effects of treatments used for cleavage and aggregation experi-
ments on intracellular calcium levels weremeasured using the protocol
described in Section 2.7; however, the incubations were performed at
37 °C with 2× diluted Calcium 5 in BSS and the recordings were per-
formed over a period of 30 min after addition of treatment. Max ratios
of quantiﬁed traces were calculated as peak responses relative to the
baseline before treatment.
2.8.2. Ataxin-3 cleavage
Neurons were treated for 30min at 37 °Cwith BSS containing either
100 μM glutamate/10 μM glycine, 100 μM ATP (Sigma-Aldrich, A6419),
1 mM dibucaine (Sigma-Aldrich, D0638) or 0.08–20 μM ionomycin
(Sigma-Aldrich, I0634). For calpain inhibition, cells were pre-treated
with 200 μM calpeptin for 30 min before adding 100 μM glutamate/
10 μM glycine and calpeptin for 30 min. After washing 3× in BSS the
cells were harvested in accordance with the Koch protocol (Koch et
al., 2011), with the exception that debri and DNA was removed fromFig. 1. Generation and characterization of SCA3 iPSC lines. A: Timeline of iPSC generation. B: SC
S1A). C: SCA3 iPSC lines (A8 and B1) and parental ﬁbroblasts (H241, H249) were harvested in
values were normalized to the geometric mean of Hsp90AB1, GUSB and RPL13A and fold chan
ﬁbroblasts, SCA3 iPSCs and the reference iPSCs lines K2 and K3 were harvested in triplicat
normalized to the geometric mean of Hsp90AB1, GUSB and RPL13A and gene expression wa
showing expression of pluripotency markers (B1 shown, A8 in Fig. S1B). Scalebars: 100 μm.
(SMA) in plated in vitro differentiated embryoid bodies (B1 shown, A8 in Fig. S1C). Scalebars:
B1). GAPDH was used to control for equal loading. Two independent experiments were perfo
samples of SCA3 ﬁbroblasts (H241 and H249), SCA3 iPSCs (A8, A11, B1 and B11), control
determined by fragment length analysis.the lysates by centrifugation at 15,000 g for 10 min to prevent DNA-
SDS complexes.
2.8.3. Ataxin-3 aggregation
The ataxin-3 aggregation protocol published by Koch et al. was ap-
plied (Koch et al., 2011). One T25 ﬂask 4–10 weeks old neurons was
treated 2× 30min or 90min at 37 °Cwith 100 μMglutamate/10 μMgly-
cine in BSS. A sonication step (5 s 10%, 5 s 50%, repeated 3 times) was
introduced after the addition of 2% SDS, to dissolveDNA-SDS complexes.
An ultracentrifugation protocol was also applied to detect smaller
SDS-insoluble ataxin-3 aggregates. Neurons were detached with
accutase and lysed for 15min on ice in 250 μl cellyticM cell lysis reagent
(Sigma-Aldrich, C2978)with 1 complete protease inhibitor cocktail tab-
let/40 ml buffer per T25 ﬂask. Samples were sonicated (5 s 10% + 5 s
50%, repeat 3 times) on ice. 2% SDS (IBI scientiﬁc, IB07062) was added
to the cell lysates before the samples were spun at 20,000 g for
30 min. The supernatants were spun at 186,000 g for 30 min. Before
analysis the pellets were thawed and incubated in formic acid (Merck
Millipore, 11670) at 37 °C for 16 h to dissolve SDS-insoluble ataxin-3 ag-
gregates and pH was adjusted with 2 M Tris-base before western blot
analysis.
2.9. MTT assay
Percentage metabolizing cells was measured with a 3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay.
Neurons were incubated with 0.5 mg/ml MTT (Sigma-Aldrich, M2128)
dissolved in NMM for 1 h at 37 °C. medium was removed and crystals
were dissolved with 95% isopropanol (ThermoFisher Scientiﬁc,
10477070)/5% formic acid. Absorbance was measured at 570 nm and
690 nm, and the percentage ofmetabolizing cellswas calculated as absor-
bance (570 nm)minus absorbance (690 nm) expressed as percent of BSS
treated cells.
3. Results
3.1. SCA3 iPSCs showno integration of episomal plasmids, have normal kar-
yotypes and are pluripotent
Skin ﬁbroblasts from SCA3 patients were isolated and
reprogrammed to iPSCs by means of a plasmid-based integration-free
methodology (Fig. 1A). Two iPSC lines generated from each of two
SCA3 patients (A and B) were investigated in this study (iPSC lines
SCA3.A8 (A8), SCA3.A11 (A11), SCA3.B1 (B1) and SCA3.B11 (B11)).
The characterizations of A11 and B11 have recently been published
(Hansen et al., 2016a, 2016b). The remaining iPSC lines, A8 and B1,
displayed similar characteristics (Fig. 1). Both iPSC lines had struc-
turally and numerically normal karyotypes (46, XY) (Fig. 1B and
S1A) and did not contain DNA originating from episomal plasmids
(Fig. 1C). Pluripotency was veriﬁed by expression of pluripotency
markers at the mRNA (OCT4, NANOG, SOX2 and LIN28) and protein
level (OCT4, NANOG, TRA-60-1, TRA-81-1, SSEA-3 and SSEA-4)
(Fig. 1D-E, S1B). The gene expression levels were comparable toA3 iPSCs were karyotyped. At least 10 metaphases were examined (B1 shown, A8 in Fig.
duplicates and tested for integration of episomal plasmids by qPCR on genomic DNA. CT-
ge relative to ﬁbroblasts was calculated using the ΔΔCT –method (mean ± S.D). D: SCA3
es and reverse transcribed to cDNA for qPCR of pluripotency markers. CT-values were
s calculated relative to ﬁbroblasts (mean ± S.D). E: Fluorescent immunocytochemistry
F: Fluorescent immunocytochemistry for α-fetoprotein (AFP) and smooth muscle actin
100 μm. G: Western blot showing ataxin-3 protein in SCA3 ﬁbroblasts and iPSCs (A8 and
rmed and a representative blot is shown. H: Genomic DNA was isolated from duplicate
ﬁbroblasts (NHDF) and control iPSCs (K1, K2 and K3). The CAG-repeat lengths were
309S.K. Hansen et al. / Stem Cell Research 17 (2016) 306–317the levels in the well-characterized iPSC lines K2 and K3. In addition,
SCA3 iPSCs could spontaneously differentiate into mesoderm ex-
pressing smooth muscle actin (SMA) and endoderm expressing α-fetoprotein (AFP) in vitro (Fig. 1F and S1B). Differentiation to
ectoderm was demonstrated by directed neuronal differentiation
(Section 3.3).
Fig. 2. Gene expression of neuronal markers during neural differentiation. A: Overview of the differentiation of iPSCs to NSCs using PSC Neural induction medium (NIM). Abbreviations:
neuronal expansion medium (NEM), Neuronal medium (NM). B: Overview of the neuronal maturation protocol. Abbreviations: Brain-derived neurotrophic factor (BDNF), glial cell line-
derived neurotrophic factor (GDNF), ascorbic acid (AA), dibutyryl cyclic adenosine monophosphate (db-cAMP). C: iPSCs, NSCs and neurons were harvested in quadruplicates. cDNA of
adult whole brain (aWB) was run as a positive control. Gene expression of pluripotency, NSC and neuronal markers were investigated by qPCR. CT-values were normalized to the
geometric mean of Hsp90AB1, GUSB and RPL13A and gene expression was calculated in relation to iPSCs (mean ± S.D).
310 S.K. Hansen et al. / Stem Cell Research 17 (2016) 306–3173.2. SCA3 iPSCs express ataxin-3 with expanded polyQ repeats
The expression of normal and expanded ataxin-3 protein was de-
tected in SCA3 ﬁbroblasts and iPSCs (Fig. 1G). Fragment length analysis
conﬁrmed that the disease alleles were 84 repeats (A8) and 73 repeats
(B1) (Fig. 1H).3.3. iPSC-derived neurons express neuronal markers, respond to neuro-
transmitters and display coordinated spontaneous calcium oscillations
SCA3 and control iPSCswere differentiated to NSCs and subsequent-
ly to neurons by the protocol illustrated in Fig. 2A and B. All neuronal
lines expressed ataxin-3 protein of expected lengths (Fig. 3C) and it
Fig. 3. Protein expression of NSC and neuronal markers, neurotransmitter response and spontaneous calcium oscillations in neuronal cultures. Neuronal differentiation was performed
according to Fig. 2A-B (wo db-cAMP d21–28). A: Protein expression of NSC- and neuronal markers in NSCs investigated by ﬂuorescent immunocytochemistry (A11 shown, K1, K2, K3,
B1, B11 in Fig. S2). Scalebars: 100 μm. B: Protein expression of NSC-, neuronal- and glial markers, and ataxin-3 detected by ﬂuorescent immunocytochemistry in neurons (A11 shown,
K1, K2, K3, B1, B11 in Fig. S3, S4). Scalebars: 100 μm. C: Western blot showing ataxin-3 expression neurons. GAPDH was used as a loading control. D: Protein expression of neuronal
markers determined by western blot with neurons. GAPDH was run as a loading control. A ladder with 6 Tau isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R and 2N4R) is shown. E:
Intracellular calcium in response to 300 μM glutamate/10 μM glycine (GG), 100 μM 5-hydroxy-tryptamine (5-HT), 25 mM potassium (K+), 100 μM γ-aminobutyric acid (GABA),
300 μM acetylcholine (Ach) and 100 μM dopamine (DA) was measured in quadruplicate wells with neurons. All four tracks are shown on the graphs (A11 shown, K1, K2, K3, B1, B11
in Fig. S5, S6). F: Synchronized spontaneous calcium oscillations were measured in quadruplicate wells with neuronal cultures. 1 μM TTX was added after 30 min. One representative
trace is presented for each neuronal line (a11 shown, K1, K2, K3, B1, B11 in Fig. S7).
311S.K. Hansen et al. / Stem Cell Research 17 (2016) 306–317was located in both soma and neurites of the neurons as expected (Fig.
3B and S4). Gene expression of the pluripotency marker OCT4was sub-
stantially decreased in NSCs and neurons compared to iPSCs (Fig. 2C)
and OCT4 protein could not be detected in the neuronal cultures (datanot shown). NSCs and neurons showed similar mRNA upregulation of
the NSC marker NES (Nestin) (Fig. 2C). Most NSCs expressed Nestin
and Vimentin protein (Fig. 3A and S2), while only few Nestin positive
cells were present in the neuronal cultures (Fig. 3B and S4). The
Fig. 4. Attempt to detect SDS-insoluble ataxin-3 aggregates in iPSCs derived neurons. Neural differentiation was performed according to Fig. 2A-B (with db-cAMP d21–28). A: The
intracellular calcium levels in response to glutamate (6.25–200 μM) combined with 10 μM glycine were investigated in quadruplicate wells (K2). A trace with 100 μM glutamate and
10 μM glycine (GG) is shown as an example. B: Overview of Koch's protocol for detection of SDS-insoluble ataxin-3 aggregates. C-E: Investigation of SDS-insoluble ataxin-3 aggregates
using Koch's protocol. Neuronal cultures were derived from K2, A11 and B1 according to Fig. 2A-B, but were additionally cultured in maturation medium with all factors for 10 weeks.
C: Veriﬁcation of intracellular calcium response to GG in triplicate wells. D: Western blots of input samples. Cells were treated for 2 × 30 min with GG and left to recover for 24 h
before Koch's protocol for detection of SDS-insoluble aggregates was performed. GAPDH was used as loading control. E: Western blot of SDS-insoluble fractions. F: Overview of the
ultracentrifugation protocol for detection of SDS-insoluble ataxin-3 aggregates. G-I: Investigation of SDS-insoluble ataxin-3 aggregates using the ultracentrifugation protocol. Neuronal
cultures were derived from K2 and A8. G: Conﬁrmation of intracellular calcium response to GG performed in triplicates. H: Western blot of input samples. Neuronal cultures were
treated 2 × 30 min with GG and left to recover for 24 h. GAPDH was run as a loading control. I: Western blot of SDS-insoluble fractions.
312 S.K. Hansen et al. / Stem Cell Research 17 (2016) 306–317proliferationmarker Ki-67was expressed in a higher proportion of cells
in NSC cultures compared to neuronal cultures (Fig. 3A, B, S2 and S4).
The pan-neuronal markers TUBB3 (βIIItub), MAP2 (MAP2), MAPT
(Tau), RBFOX3 (NeuN) and SYN1 (Synapsin 1) were expressed at both
mRNA and protein levels in the neuronal cultures (Fig. 2C, 3B, D, S3,
and S4). The gene expression levels were higher than, or comparable
to, those of adult whole brain, except for the postmitotic marker
RBFOX3 (NeuN) and the presynaptic marker SYN1 (Synapsin 1) which
were both expressed at levels comparable to that of fetal whole brain.
In accordance, only a fraction of the cells expressed NeuN and Synapsin
1 protein (Figs. 3B, 4D and S3). Furthermore, only two low bands of Tau
proteinwere present in the neurons (Fig. 3D). The lower band being the
embryonal isoform 0N3R Tau, and the upper band most likely being
phosphorylated Tau species, based on our previous experiments (datanot shown). None of the additional ﬁve isoforms expressed in adult
human brain were present (Goedert and Jakes, 1990). The hindbrain
genes, HOXA2 and GBX2 (Kirkeby et al., 2012) were upregulated in
NSCs and neuronal cultures at a level comparable to fetal hindbrain. In
contrast, the marker of caudal hindbrain HOXA4 (Philippidou and
Dasen, 2013) was not expressed (data not shown). The gene expression
of FOXG1 and LHX2 primarily expressed in the forebrain (Kirkeby et al.,
2012), were comparable to fetal hindbrain and lower than fetal and
adult whole brain levels (Fig. 2C). Analysis of gene expression levels of
neuronal subtype markers revealed that the gene expression of CHAT
(cholinergic neurons) was comparable to that of adult whole brain
(Fig. 2C), and that GAD1 (GAD67, GABAergic neurons) was slightly up-
regulated in neurons compared to iPSCs; however, not to the level ob-
served in adult whole brain (Fig. 2C). GAD65/67 protein was not
Fig. 5. Induction of ataxin-3 cleavage. Neural differentiation was performed according to Fig. 2A-B (with db-cAMP d21–28). A-B: Effect of extracellular calcium (Ca) andmagnesium (Mg)
concentration on ataxin-3 cleavage was tested in neurons derived from K2, A11 and B1. A: Intracellular calcium response to 100 μM glutamate/10 μM glycine (GG) in BSS buffer
supplemented with normal (1.8 mM) or high (3.7 mM) CaCl2 combined with either normal (0.8 mM) or no MgCl2 was investigated in duplicate wells. B: Neuronal cultures were
treated with GG for 30 min and directly harvested for western blot. Ataxin-3 fragments are marked with black arrows while α-fodrin fragments are marked with open arrowheads.
GAPDH was used as a loading control and βIIItub was used to compare the degree of neural differentiation. The extra bands detected at approximately 50 kDa and 60 kDa on the
βIIItub blot are weak traces of ataxin-3. C–D: Effect of different treatments on ataxin-3 cleavage in neurons derived from K2, A11 and B1. C: Intracellular calcium response to GG,
100 μM ATP and 20 μM ionomycin was tested in duplicate wells. D: Neuronal cultures were treated with GG, 1 mM dibucaine, 100 μM ATP or 20 μM Ionomycin for 30 min and
harvested directly. When treated with 200 μM calpeptin, cells were pretreated for 30 min with calpeptin before treatment with GG + calpeptin for 30 min. Ataxin-3 fragments are
marked with black arrowheads and α-fodrin fragments are marked with white arrowheads. GAPDH was used as a loading control and βIIItub was used to detect the degree of neural
differentiation. The extra bands detected at approximately 50 kDa and 60 kDa on the βIIItub blot are weak traces of ataxin-3. Where blots are divided by black vertical lines, irrelevant
samples were removed.
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cultures expressed TH (dopaminergic/adrenergic marker) (Fig. 3B and
S3). SLC17A7 (vGLUT1, glutamatergic neurons) was neither detected
at the mRNA nor the protein level (data not shown). Furthermore,
mRNA of the serotonergic marker TPH2 was not expressed (data not
shown). Themajority of the neuronal cultures contained few cells stain-
ing positive for the astrocyte marker GFAP (Fig. 3B and S4).
Image based assessment of changes in intracellular calcium levels
was used to evaluate the functionality of the neurons. The neurotrans-
mitters, GABA and glycine/glutamate, and membrane depolarization
with potassium resulted in a large rise in intracellular calcium levels in
all neuronal cultures (Fig. 3E, S5 and S6), while acetylcholine caused a
minor and serotonin and dopamine no response. Detection of spontane-
ous calcium oscillations indicated that spontaneous ﬁring was synchro-
nized between the majorities of the neurons in the 96-wells. Theoscillations could be abrogated by the voltage-gated sodium channel
blocker TTX (Fig. 3F and S7).
3.4. Glutamate treatments of iPSC derived neurons did not induce SDS-in-
soluble ataxin-3 aggregates
Exposing SCA3 iPSC-derived neurons to 100 μM glutamate has been
reported to induce SDS-insoluble ataxin-3 aggregates (Koch et al.,
2011). 100 μM glutamate was also used in the present study as this
concentration resulted in maximal increase in intracellular calcium
(Fig. 4A). Both the protocol published by Koch et al. (Fig. 4B) and a
protocol based on ultracentrifugation (Fig. 4F) were applied to inves-
tigate if a patient-speciﬁc ataxin-3 aggregation phenotype could be
identiﬁed. Increase of intracellular calcium in response to the applied
treatments was measured in all batches of neurons used for
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10 weeks old neurons investigated with the Koch protocol (Fig. 4C-
E and 6B-D) nor 4 weeks old neurons investigated with the ultracen-
trifugation protocol (Fig. 5G-I) resulted in detectable SDS-insoluble
aggregates after treatment with 100 μM glutamate/10 μM glycine
for 2 × 30 min followed by 24 h recovery. Increasing the glutamate
and glycine stimulation period to 90 min did not induce SDS-insoluble aggregates detectable by Koch's protocol in 4 weeks old
neurons (Fig. 6B-D). db-cAMP has been reported to induce protea-
some activity (Myeku et al., 2012) and could thereby potentially
increase the degradation of exp.-ataxin-3 species. However, with-
drawal of db-cAMP for the last week of the differentiation also did
not induce SDS-insoluble ataxin-3 aggregates detectable by Koch's
protocol in 4 weeks old neurons (Fig. 6B-D).
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It has been hypothesized that the glutamate induced intracellular
calcium increase activates calpain-mediated ataxin-3 cleavage and
thus induces the formation of SDS-insoluble ataxin-3 aggregates
(Koch et al., 2011). We decided to test the capability of multiple treat-
ments to induce ataxin-3 cleavage via calcium activated calpain and
hence identify conditions that potentially induce ataxin-3 aggregation.
The calpain substrateα-fodrinwas used as an indicator of calpain activ-
ity. Calpain seemed to be active to a low extend in the neurons, as the
basal level of ataxin-3 and α-fodrin fragments could be partially de-
creased by the calpain inhibitor calpeptin. However, ataxin-3 and α-
fodrin cleavage could only be slightly induced by the calpain activator
dibucaine (Zhang et al., 2011) (Fig. 5D).
We optimized the glutamate stimulation conditions tomaximize the
resulting increase in intracellular calcium (Fig. 5A). Doubling the extra-
cellular calcium concentration resulted in an increase of intracellular
calcium in response to glutamate treatment (Fig. 5A), whereas no effect
wasdetected uponmagnesiumwithdrawal. No systematic effects of cal-
cium and magnesium concentrations were observed on the cleavage of
ataxin-3 or α-fodrin (Fig. 5B). Furthermore, the effect of the P2Y
purinoreceptor agonist ATP and the calcium ionophore ionomycin
were tested. ATP had no effect, but ionomycin (20 μM) gave rise to a
massive increase in intracellular calcium levels (Fig. 5C) and a marked
increase in both ataxin-3 and α-fodrin cleavage (Fig. 5D).
3.6. Ionomycin could not induce ataxin-3 aggregation selectively in SCA3
iPSC derived neurons
Concentration-response experiments with ionomycin established
that 5 μM ionomycin was the lowest concentration giving a maximal re-
sponse in intracellular calcium level (Fig. 6A). The ability of 5 μM
ionomycin to induce SDS-insoluble ataxin-3 aggregates was tested with
the Koch protocol on 4 weeks old neurons. Aggregates were detected
in both control and SCA3 neuronal cultures (Fig. 6D) and therefore
were most likely not facilitated by exp.-ataxin-3. During harvest for the
aggregation experiment, it was noticed that the cells treated with
ionomycin detached more readily compared with other conditions. To-
gether with massive fragmentation of α-fodrin and low levels of
ataxin-3 and βIIItub (Fig. 6C), this indicated that 5 μM ionomycin was
toxic to the cells in the stimulation paradigmapplied (2× 30min stimuli,
24 h recovery). It was investigated if the concentration of ionomycin
could be decreased (0.08, 0.4, 2.0 μM) in order to avoid toxicity. 2 μM
ionomycin appeared toxic when tested just after treatment (Fig. 6G);
however, this effect was transient and disappeared after 24 h recovery
(Fig. 6H). Furthermore, lower ionomycin concentrations (0.08, 0.4 and
2.0 μM) were unable to induce ataxin-3 or α-fodrin cleavage (Fig. 6F).
Taken together,we could not identify an ionomycin concentration induc-
ing ataxin-3 cleavage without showing general cytotoxicity.
4. Discussion
In general, studies of human neurodegenerative disease mecha-
nisms are limited by the lack of human neuronal in vitro models. In
this study, we report iPSC lines that can form the basis for developingFig. 6. Effect of ionomycin on ataxin-3 cleavage and aggregation. Neural differentiation of K2, A1
3 aggregates using theKochprotocol. A: Intracellular calcium levels in response to 0.2–20 μM ion
an example. B: Intracellular calcium response to 100 μM glutamate/10 μM glycine (GG) was m
90 min with GG or 5 μM ionomycin and left to recover for 24 h before testing aggregation. At
with open arrowheads. GAPDH was used as a loading control and βIIItub was used to monitor
and 60 kDa on the βIIItub blot are remnants of ataxin-3. D: SDS-insoluble fractions. Ataxin-3 f
avoid toxicity. E: Intracellular calcium levels in response to 0.04–2 μM ionomycin was teste
30 min and harvested for western blot. Ataxin-3 fragments are marked with black arrowhe
loading control and βIIItub was used to indicate the degree of neural differentiation. The extra
ataxin-3. Where blots are divided by black vertical lines, irrelevant samples were removed
30 min and MTT assay was performed G: without recovery or H: with 24 h recovery.a new improved model system for studying SCA3 disease mechanisms.
iPSCs generated from two SCA3 patients (four lines) and one healthy in-
dividual (three lines) by reprogramming of dermal ﬁbroblasts with an
integration-free method were differentiated into neurons. As the hind-
brain is particularly affected by neurodegeneration in SCA3, we applied
a neuronal differentiation protocol, which has been reported to give rise
to NSCs expressing hindbrain genes such as HOXA2 and HOXB2 (Yan et
al., 2013). The applied neuronal differentiation method generated large
amounts of NSCs from a single neural induction (1× 6-well of iPSCs can
generate 400 vials of 4 million p4 NSCs) which could be easily obtained
and frozen. Differentiations from these NSCs have proven to be highly
reproducible in our laboratory. Expression of the hindbrain genes
HOXA2 and GBX2 were increased in all derived NSCs and neurons to
levels comparable to fetal hindbrain. In addition, the forebrain markers
FOXG1 and LHX2were also expressed at the level of fetal hindbrain. To-
gether, these data indicate that the applied differentiation paradigm re-
sulted in neuronswith caudal identity. It has to be kept inmind that the
regional markers are transiently expressed during embryo develop-
ment and that further analysis is need to conﬁrm protein expression
and determine the percentage of neurons with hindbrain identity. In-
vestigation of the neuronal subtype indicated cholinergic identity
based on mRNA expression when comparing to adult whole brain. Fur-
thermore low expression of GABAergic and dopaminergicmarkerswere
also observed. Overall, these results suggest the presence of cholinergic
neurons of hindbrain origin. Neuronal cultures from all iPSC lines
expressed a range of pan-neuronal markers (TUBB3 (βIIItub), MAP2
(MAP2), MAPT (Tau), RBFOX3 (NeuN)) and SYN1 (Synapsin 1) with
only minor differences in mRNA expression levels between the neuro-
nal cultures. The neurons seemed to have reached a certain state of ma-
turity as the postmitotic marker NeuN and the presynaptic marker
Synapsin 1 were expressed in subsets of neurons. The gene expression
levels of RBFOX3 (NeuN) and SYN1 (Synapsin 1) in iPSC-derived neu-
rons were at the level of fetal whole brain but lower than in adult
whole brain indicating that some or all of the cells were not fully ma-
ture. In line with these observations, only the embryonic isoform of
Tau 0N3R (Goedert and Jakes, 1990) was expressed. So far, only one
study has detected all adult Tau isoforms in iPSC-derived neurons. No-
ticeably, they did not arise until day 365 of cell culture (Sposito et al.,
2015).
All iPSC-derived neurons demonstrated expression of functional
neurotransmitter receptors, responding to glutamate/glycine, GABA
and to a lower extend to acetylcholine. Interestingly, the neuronal cul-
tures also developed synchronized spontaneous calcium oscillations,
which were likely to reﬂect action potential ﬁring (Robinson et al.,
1993). This was conﬁrmed as the inhibitor of voltage-gated sodium
channels, TTX, blocked the synchronization of the oscillations.
In vivo, spontaneous calcium oscillations occur in individual neural
precursors and immature neurons in early development where they
regulate several processes (Blankenship and Feller, 2009). Both during
late embryonic and early postnatal development, neurons from many
different areas of the CNS have been shown to form synchronized oscil-
latory networks consisting of bursts of action potentials separated by
periods without ﬁring. Such networks are believed to be mediated by
gap junctions during embryonic development, while chemical synaptic
transmission tends to mediate themajority of the network activity later1 and B1was performed according to Fig. 2A-B. A–D: Investigation of SDS-insoluble ataxin-
omycinwere investigated inquadruplicatewells. A tracewith 5 μM ionomycin is shownas
easured in triplicates. C: Input samples. Neuronal cultures were treated for 2 × 30 min or
axin-3 fragments are marked with black arrowheads and α-fodrin fragments are marked
the degree of neural differentiation. The extra signals detected at approximately 50 kDa
ragments are marked with black arrowheads. E-H: Adjustment of the ionomycin dosis to
d in duplicate wells. F: Neuronal cultures were treated with 0.04–2 μM ionomycin for
ads and α-fodrin fragments are marked with open arrowheads. GADPH was used as a
signals detected at approximately 50 kDa and 60 kDa on the βIIItub blot are remnants of
. G-H: Fraction of metabolizing cells. Duplicate wells were treated with ionomycin for
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Sutor and Hagerty, 2005). The occurrence of spontaneous synchronized
calcium oscillations as well as the expression of the presynaptic protein
Synapsin 1 in our neuronal cultures therefore implies a certain level of
neuronal maturity. The mediation by chemical synapses could be con-
ﬁrmedby applying inhibitors or knock down of neurotransmitter recep-
tors or gab junctions (Blankenship and Feller, 2009). In vitro,
synchronized network activity mediated by chemical synapses has
been observed in primary (Dravid and Murray, 2004) and ESC derived
neurons (Heikkilä et al., 2009). Only recently, such network activity
was reported in one study of iPSC derived neurons. However, these neu-
rons had to be cultured for 70–140 days and form 3D structures before
regular spontaneous oscillations dependent on chemical synaptic activ-
ity were observed (Kirwan et al., 2015). In our neuronal cultures, syn-
chronized spontaneous activity occurred robustly in all cell lines
already after 28 days of maturation, which indicated that they have
reached a relatively advanced state of maturity compared to themajor-
ity of other iPSC derived neurons.
A key element of SCA3 is the presence of SDS-insoluble ataxin-3 ag-
gregates. Herewe strived to induce aggregate formationwith glutamate
stimulation as described previously (Koch et al., 2011), yet, without suc-
cess. As we were unable to obtain a positive control such as transgenic
mouse brain with ataxin-3 aggregates, it was not possible to evaluate
the protocols for detection of ataxin-3 aggregates. In addition, several
biological traits of the investigated neurons could have inhibited the for-
mation and accumulation of aggregates. Firstly, the neuronal differenti-
ation protocol applied by Koch et al. was signiﬁcantly different than
ours, and likely to have generated a different neuronal population. In
support of this, their neurons expressed the GABAergic marker GABA,
whereas our cells only expressed GABAergicmarkermRNA but not pro-
tein. Secondly, it is possible that our neurons are better at clearing
cleaved and aggregated ataxin-3. For example, db-cAMP, has been
shown to increase proteasomal activity (Myeku et al., 2012) and is
used in a 800× lower concentration in the maturation protocol applied
by Koch et al. compared to our protocol. However, withdrawal of db-
cAMP for the last week of maturation did not induce SDS-insoluble ag-
gregation in our experiments. Finally, our neurons might express less
calpain or the calpain-activity might be decreased, reducing the cleav-
age of exp.-ataxin-3 and, thus, the formation of aggregates. For example,
the spontaneous calciumoscillations caused by action potential ﬁring in
the neurons could induce prolonged calpain activation, which is known
to upregulate the expression of the endogenous calpain inhibitor
calpastatin (Averna et al., 2003). Supporting this theory, we were un-
able to induce high levels of calpain mediated cleavage of ataxin-3 and
the calpain substrateα-fodrin using several ways to increase intracellu-
lar calcium levels in order to activate calpain, including increased gluta-
mate response, treatment with a calpain activator (dibucaine) and a
purinoreceptor agonist (ATP). The ionophore ionomycin, however, in-
creased ataxin-3 and α-fodrin cleavage, but it was not possible to ﬁnd
an ionomycin concentration, which induced ataxin-3 cleavage without
being toxic to the neurons. In further experiments, it will be relevant
to explore other methods, such as induction of oxidative stress,
proteasomal inhibition or inhibition of autophagy to either induce ag-
gregation or cause accumulation of aggregates by inhibiting their
degradation.
Although aggregation is a key feature of SCA3, neuronal intra-nucle-
ar inclusions have also been detected in unaffected parts of SCA3 brain
(Yamada et al., 2004), indicating that aggregation alone does not
cause neurodegeneration. Indeed, no toxicity was induced by the SDS-
insoluble aggregates observed in the study by Koch et al. Furthermore,
both neurodegeneration and behavioral phenotypes have been ob-
served in a SCA3 mouse model, which did not have neuronal intra-nu-
clear inclusions or SDS-insoluble aggregates (Silva-Fernandes et al.,
2010), indicating that the presence of aggregates is not needed to
cause a SCA3 phenotype. The iPSC derived neurons generated in this
study, might therefore serve to investigate disease mechanisms notnecessarily related to ataxin-3 aggregation, for example alterations in
WT ataxin-3 functions caused by the expanded polyQ repeat.
5. Conclusion
We have successfully generated SCA3 patient-derived iPSCs by an
integration-free method. Four SCA3 iPSC lines and three control iPSC
lineswere differentiated into neuronswhich showed similar expression
of pan-neuronal markers and responded to several neurotransmitters.
Furthermore, after only 28 days of maturation the expression of the
postmitotic marker NeuN and the pre-synaptic marker Synapsin 1 to-
gether with synchronized spontaneous calcium oscillations implied a
relatively advanced neuronal maturity in comparison with existing
iPSC-derived neurons. Although SDS-insoluble aggregates could not be
induced in these neurons we believe that the generated neurons could
potentially be it a valuable tool for modeling SCA3.
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